Calliditas Therapeutics AB (publ)

OM:CALTX Stock Report

Market Cap: SEK 11.2b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Calliditas Therapeutics Balance Sheet Health

Financial Health criteria checks 2/6

Calliditas Therapeutics has a total shareholder equity of SEK106.8M and total debt of SEK982.5M, which brings its debt-to-equity ratio to 920%. Its total assets and total liabilities are SEK1.7B and SEK1.6B respectively.

Key information

920.0%

Debt to equity ratio

SEK 982.49m

Debt

Interest coverage ration/a
CashSEK 797.28m
EquitySEK 106.79m
Total liabilitiesSEK 1.64b
Total assetsSEK 1.75b

Recent financial health updates

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Jan 12
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

Sep 22
Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Feb 24
Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Recent updates

Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results

Feb 24
Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Jan 12
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost

Dec 22
Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost

Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

Sep 22
Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today

Aug 19
What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today

Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%

May 26
Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%

Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Feb 24
Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Nov 25
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%

Aug 24
Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%

Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?

Aug 03
Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?

Financial Position Analysis

Short Term Liabilities: CALTX's short term assets (SEK1.2B) exceed its short term liabilities (SEK429.8M).

Long Term Liabilities: CALTX's short term assets (SEK1.2B) do not cover its long term liabilities (SEK1.2B).


Debt to Equity History and Analysis

Debt Level: CALTX's net debt to equity ratio (173.4%) is considered high.

Reducing Debt: CALTX's debt to equity ratio has increased from 0% to 920% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CALTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CALTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies